ReviewTreatments in respiratory medicine2006
Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy.
Review in Treatments in respiratory medicine, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Toll-Like Receptor 9 Aggravates Pulmonary Fibrosis by Promoting NLRP3-Mediated Pyroptosis of Alveolar Epithelial Cells.Inflammation · 2024Article
- p53 and Myofibroblast Apoptosis in Organ Fibrosis.International journal of molecular sciences · 2023Review
- The Challenge of Long-Term Cultivation of Human Precision-Cut Lung Slices.The American journal of pathology · 2022Article
- Regorafenib-Attenuated, Bleomycin-Induced Pulmonary Fibrosis by Inhibiting the TGF-β1 Signaling Pathway.International journal of molecular sciences · 2021Article
- Angiotensin Receptor Blockers and Subclinical Interstitial Lung Disease: The MESA Study.Annals of the American Thoracic Society · 2019Article
- Inactivation of nuclear histone deacetylases by EP300 disrupts the MiCEE complex in idiopathic pulmonary fibrosis.Nature communications · 2019Article
- Application of Isobaric Tags for Relative and Absolute Quantification (iTRAQ) Coupled with Two-Dimensional Liquid Chromatography/Tandem Mass Spectrometry in Quantitative Proteomic Analysis for Discovery of Serum Biomarkers for Idiopathic Pulmonary Fibrosis.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Article
- Association of HLA and cytokine gene polymorphisms with idiopathic pulmonary fibrosis.The Kaohsiung journal of medical sciences · 2015Article
- Peptide-mediated inhibition of mitogen-activated protein kinase-activated protein kinase-2 ameliorates bleomycin-induced pulmonary fibrosis.American journal of respiratory cell and molecular biology · 2013Article
- X-linked inhibitor of apoptosis regulates lung fibroblast resistance to Fas-mediated apoptosis.American journal of respiratory cell and molecular biology · 2013Article
- Article
- Increased survivin expression contributes to apoptosis-resistance in IPF fibroblasts.Advances in bioscience and biotechnology (Print) · 2012Article
- Survivin expression induced by endothelin-1 promotes myofibroblast resistance to apoptosis.The international journal of biochemistry & cell biology · 2012Article
- Panax notoginseng Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice.Evidence-based complementary and alternative medicine : eCAM · 2011Article
- Phosphodiesterase 6 subunits are expressed and altered in idiopathic pulmonary fibrosis.Respiratory research · 2010Article
- Endothelin-1 and transforming growth factor-beta1 independently induce fibroblast resistance to apoptosis via AKT activation.American journal of respiratory cell and molecular biology · 2009Article
- Modulation of TGFbeta1-dependent myofibroblast differentiation by hyaluronan.The American journal of pathology · 2009Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and usually fatal pulmonary disease for which there are no proven drug therapies. Anti-inflammatory and immunosuppressive agents have been largely ineffective. The precise relationship of IPF to other idiopathic interstitial pneumonias (IIPs) is not known, despite the observation that different histopathologic patterns of IIP may coexist in the same patient. We propose that these different histopathologic 'reaction' patterns may be determined by complex interactions between host and environmental factors that alter the local alveolar milieu. Recent paradigms in IPF pathogenesis have focused on dysregulated epithelial-mesenchymal interactions, an imbalance in T(H)1/T(H)2 cytokine profile and potential roles for aberrant angiogenesis. In this review, we discuss these evolving concepts in disease pathogenesis and emerging therapies designed to target pro-fibrogenic pathways in IPF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.